Investor Overview

Our Investor Information

Company Overview

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Annual Report
Press Releases
November 27, 2020
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
November 4, 2020
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020
Upcoming Events
More events are coming soon.
Investor FAQs
More FAQs are coming soon.

Founded

Delaware, November 2008

Headquarters

222 Berkeley Street, 12th Floor
Boston, MA 02116
Phone: 857-264-4280

CUSIP number

76243J105

Transfer Agent

Computershare Trust Company, Inc.
250 Royall Street
Canton, MA 02021
www.computershare.com
US Phone: +1-800-962-4284
International Phone: + 1-781-575-3120